TABLE 5

Oseltamivir Dosing Recommendations for Antiviral Treatment and Chemoprophylaxis of Children Younger Than 1 Year With Suspected or Confirmed Novel Influenza A (H1N1)

AgeTreatment Dose for 5 dChemoprophylaxis Dose for 10 d
<3 mo12 mg twice dailyNot recommended unless situation judged critical because of limited data on use in this age group
3–5 mo20 mg twice daily20 mg once daily
6–11 mo25 mg twice daily25 mg once daily
  • This emergency-use authorization was issued by the FDA on April 28, 2009, for a period of 1 year and was intended for use as guidance to clinicians who were considering use of oseltamivir for preventing influenza in infants younger than 1 year. However, seasonal influenza A (H3N2) and B viruses have similar sensitivity to oseltamivir. As of June 2009, nearly all seasonal influenza A (H1N1) viruses were resistant to oseltamivir.

  • Data source: Centers for Disease Control and Prevention. Antiviral agents for the prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009; In press.